Nautilus Biotechnology (NAUT) Insider Nazem Buys 45,000 Shares
Farzad Nazem recently purchased 45,000 shares of NAUT.
Reviewed by automated data checks against the source filing. How we make and check alerts
Farzad Nazem bought 45,000 shares of Nautilus Biotechnology, Inc. ($NAUT) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAUT is down 0.4% after 1 week, down 25.9% after 1 month and down 9.7% to date (from the $2.28 close on Jun 18, 2026).
NAUT
Nautilus Biotechnology, Inc.
Key Points
- Farzad Nazem acquired 45,000 shares of NAUT on June 18, 2026, as part of an insider buy.
- Shares of NAUT traded near $2.31 on Tuesday, with institutional interest from firms like Vanguard Capital Management.
- Analysts from Guggenheim maintained a 'buy' rating with a $4.00 target, while Goldman Sachs rated it 'sell' at $1.75.
Get $NAUT trade alerts by text
We text you when insiders, Congress or big funds trade $NAUT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nautilus Biotechnology, Inc. alert may contain errors. Disclosures
Farzad Nazem, an insider at NAUT, recently purchased 45,000 shares of the company on June 18, 2026. This transaction was not part of a planned trading program.
Other Institutional Activity in NAUT
Several institutional investors have also shown interest in NAUT. A16Z Capital Management, L.L.C. holds 17,653,917 shares valued at about $68.5 million. Perceptive Advisors LLC has maintained its position with 12,594,211 shares worth approximately $48.9 million. Vanguard Capital Management LLC opened a new position with 2,545,597 shares valued at nearly $9.9 million. Similarly, Clearstead Advisors, LLC initiated a stake with 2,329,784 shares, valued around $9 million.
Nautilus Biotechnology, Inc. Stock Up 139.1%
Shares of NAUT traded near $2.31 on Tuesday. The stock has seen various institutional activities, suggesting a mix of investor sentiment. The company's market performance is under scrutiny as insiders and institutions adjust their holdings.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, several insiders, including Farzad Nazem, each bought 45,000 shares of NAUT. This group included Matthew McIlwain, Matthew Posard, Karen Akinsanya, and Melissa B. Epperly. Additionally, Sujal Patel, the CEO, President, and Secretary, purchased 25,000 shares at an average price of $2.61 on March 4, 2026.
Analysts Set New Price Targets
On February 27, 2026, Guggenheim maintained its 'buy' rating on NAUT with a price target of $4.00. Meanwhile, Goldman Sachs had previously downgraded the stock to a 'sell' with a target of $1.75 on December 8, 2024. Morgan Stanley maintained a 'hold' rating with a $5.00 target back in July 2024.
Bottom Line
Farzad Nazem's recent purchase of 45,000 NAUT shares adds to the insider activity that investors closely watch. With institutional investors like Vanguard Capital Management taking new stakes, NAUT remains a point of interest. Analyst ratings provide a mixed outlook, with significant variations in price targets, reflecting differing views on the company's future performance.
Related Filing Alerts
Source: Farzad Nazem's Form 4 filing on $NAUT (Jun 18, 2026). Find the original filing: NAUT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts